Solvonis Therapeutics
OrganizationHeard in 2 episodes across 1 show since Aug 2026
A UK-listed biopharmaceutical company developing medicines in areas including mental health and central nervous system disorders, with esketamine-related programmes among its priorities.
Episodes
First heard
Expert statements
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Dec 2025 | 0 |
| Jan 2026 | 0 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 1 |
| Sep 2026 | 0 |
| Oct 2026 | 0 |
| Nov 2026 | 1 |
Email alert
Email me when Solvonis Therapeutics comes up on a podcast
One email a week at most, with the new episodes that mention Solvonis Therapeutics. Free, no account needed, unsubscribe in one click.
What experts have said about Solvonis Therapeutics
11 statements · 10 positive · 1 neutral
Solvonis would need Phase 2 completion and Phase 3 entry to match Transcend’s deal stage.
“We would need to complete a Phase 2 programme and be in Phase 3 to be at exactly the same stage as Transcend was”
Open the episode · S12 Ep17: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 3:19
Solvonis is materially undervalued versus US psychedelic-sector peers.
“We are materially undervalued compared to them”
Open the episode · S12 Ep17: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 5:27
Tennyson expects progress on Solvonis programs and regulatory feedback within two to four months.
“That is what I have confidence over in the next two to four months”
Open the episode · S12 Ep17: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNSListen at 10:06
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
2 episodes featuring Solvonis Therapeutics, newest first